It could stimulate robust and sustained GLP-1 secretion with minimal TGR5-mediated suppression of gallbladder emptying, which rendered 15 an ideal therapeutic method for patients with metabolic diseases such as type 2 diabetes, NASH, or inflammatory bowel disease. The gene discussed is GPBAR1; the disease is metabolic disease.